NEC and Biomy announced that they have formed a joint marketing partnership to develop and expand artificial intelligence (AI)-based analytical digital pathology platforms.
In a statement, the partners said they plan to integrate AI technologies developed by NEC and Biomy into DeepPathFinder, a cloud-based automated digital pathology analytical platform developed by Biomy. This platform uses deep learning to automatically analyze digital pathology images to classify cell and tissue types in specific regions. Furthermore, DeepPathFinder has the ability to detect immune cells, such as lymphocytes and plasma cells from hematoxylin and eosin-stained images, along with spatial biology features.
The two Tokyo-based companies said they aim to use the enhanced DeepPathFinder platform to discover new pathological biomarkers and use the data derived from pathological images to support precision medicine and treatment planning, particularly in the field of cancer care.
NEC and Biomy added that they plan to offer the resulting AI-driven digital pathology biomarker discovery tool to pharmaceutical/biotech companies and academia as an automated digital pathology platform, along with digital pathological biomarker discovery services offered through NEC and Biomy, as well as providing guidance and support for working through the regulatory approval process for medical devices that use the newly discovered biomarkers.
